Who are Xaira Therapeutics's decision-makers?
Xaira Therapeutics is led by Marc Tessier-Lavigne, CEO, with a leadership bench spanning product, science, operations, and commercialization.
- CEO
- Marc Tessier-Lavigne
- Key exec
- David Baker
- Founded
- 2024
- Employees
- Private; large launch-stage biotech team
- HQ
- South San Francisco, California
- Notable
- Neuroscientist and former Stanford president leading the company.
- Marc Tessier-LavigneCEOCEO · since 2024Neuroscientist and former Stanford president leading the company.
- David BakerCo-founder / scientific advisorFounder networkProtein-design scientist involved in the launch consortium.
- Arvind RajpalExecutive chairman / investorLaunch leadershipLife-sciences investor involved through Foresite Labs.
Who leads Xaira Therapeutics?
Marc Tessier-Lavigne serves as CEO; David Baker serves as Co-founder / scientific advisor; Arvind Rajpal serves as Executive chairman / investor. The leadership pattern reflects the company's focus on ai drug discovery.
For outreach, leadership background matters because it shows whether decisions are likely to be product-led, science-led, clinical, industrial, or government-procurement heavy.
Who actually makes buying decisions at Xaira Therapeutics?
Likely buying committees include the executive owner of AI drug discovery platform, security and compliance leaders, finance/procurement, and the technical leaders responsible for integration.
A seller should avoid starting with a generic CEO pitch unless the offer is strategic. Most practical deals will need a functional champion who owns deployment pain and a finance or operations approver.
How is Xaira Therapeutics organized as it scales?
Xaira Therapeutics's public footprint suggests a scaling private company with cross-functional teams around product, engineering, customer deployment, and go-to-market or R&D. Exact reporting lines are not public.
The safest assumption is a matrixed buying process: technical validation first, operational proof second, and executive approval for larger commitments.
As of June 2026.Sources:Xaira websiteXaira launch announcement
Xaira Therapeutics — frequently asked questions
